DeepMed Research

THOMAS JEFFERSON UNIVERSITY

🇺🇸United States

Country: 🇺🇸United States

Ownership: Private

Established: 1824-01-01

Employees: 10K

Market Cap: -

Website: http://www.jefferson.edu

Clinical Trials

Real-Time Monitoring of Chemotherapy Side-Effects in Patients With Gastrointestinal Cancers, RT-CAMSS Study

Not Applicable

Completed

Conditions: Clinical Stage 0 Esophageal Adenocarcinoma AJCC v8
Clinical Stage I Esophageal Squamous Cell Carcinoma AJCC v8
Clinical Stage I Gastric Cancer AJCC v8
Clinical Stage II Esophageal Adenocarcinoma AJCC v8
Clinical Stage II Esophageal Squamous Cell Carcinoma AJCC v8
Clinical Stage I Esophageal Adenocarcinoma AJCC v8
Clinical Stage 0 Gastric Cancer AJCC v8
Clinical Stage IIA Gastric Cancer AJCC v8
Pathologic Stage 0 Gastric Cancer AJCC v8
Pathologic Stage I Esophageal Adenocarcinoma AJCC v8

Interventions: Other: Patient Monitoring System
Other: Questionnaire Administration
Other: Consultation

First Posted Date: 2020-06-29

Last Posted Date: 2025-05-15

Lead Sponsor: Thomas Jefferson University

Target Recruit Count: 34

Registration Number: NCT04449679

Locations: 🇺🇸
Thomas Jefferson University Hospital, Philadelphia, Pennsylvania, United States

Technology-Enhanced Acceleration of Germline Evaluation for Therapy, TARGET Study

Not Applicable

Active, not recruiting

Conditions: Stage IV Prostate Cancer AJCC v8
Biochemically Recurrent Prostate Carcinoma
Stage IIIC Prostate Cancer AJCC v8
Metastatic Prostate Carcinoma
Stage IIIB Prostate Cancer AJCC v8

Interventions: Other: Genetic Counseling
Other: Interview
Genetic: Genetic Testing
Other: Internet Based Intervention
Other: Internet-Based Intervention
Other: Survey Administration

First Posted Date: 2020-06-25

Last Posted Date: 2024-01-08

Lead Sponsor: Thomas Jefferson University

Target Recruit Count: 346

Registration Number: NCT04447703

Locations: 🇺🇸
VA New York Harbor Health System- Manhattan Campus, New York, New York, United States
🇺🇸
New York University- Langone Health, New York, New York, United States
🇺🇸
Associated Medical Professions of New York, Syracuse, New York, United States

and more 2 locations

An Early Phase Study of Venetoclax, Lenalidomide, and Rituximab/Hyaluronidase in Slow-Growing Lymphomas That Have Come Back After Treatment or Have Not Responded to Treatment

Phase 1

Active, not recruiting

Conditions: Refractory Marginal Zone Lymphoma
Recurrent Indolent Adult Non-Hodgkin Lymphoma
Recurrent Follicular Lymphoma
Recurrent Marginal Zone Lymphoma
Refractory B-Cell Non-Hodgkin Lymphoma
Refractory Follicular Lymphoma
Recurrent B-Cell Non-Hodgkin Lymphoma
Refractory Indolent Adult Non-Hodgkin Lymphoma

Interventions: Drug: Venetoclax
Drug: Lenalidomide
Biological: Rituximab
Biological: Rituximab and Hyaluronidase Human

First Posted Date: 2020-06-25

Last Posted Date: 2025-05-22

Lead Sponsor: Thomas Jefferson University

Target Recruit Count: 4

Registration Number: NCT04447716

Locations: 🇺🇸
Sidney Kimmel Cancer Center at Thomas Jefferson University, Philadelphia, Pennsylvania, United States

Breast Cancer Vaccine in Combination With Pembrolizumab for Treatment of Persistent, Recurrent, or Metastatic Breast Cancer

Phase 1

Withdrawn

Conditions: Recurrent Breast Carcinoma
Prognostic Stage IV Breast Cancer AJCC v8
Metastatic Breast Carcinoma
Anatomic Stage IV Breast Cancer AJCC v8
Refractory Breast Carcinoma

Interventions: Drug: Cyclophosphamide
Biological: Allogeneic GM-CSF-secreting Breast Cancer Vaccine SV-BR-1-GM
Biological: Pembrolizumab
Biological: Recombinant Interferon Alpha 2b-like Protein
Other: Questionnaire Administration
Other: Quality of Life Assessment

First Posted Date: 2020-06-05

Last Posted Date: 2025-04-29

Lead Sponsor: Thomas Jefferson University

Registration Number: NCT04418219

Locations: 🇺🇸
Sidney Kimmel Cancer Center at Thomas Jefferson University, Philadelphia, Pennsylvania, United States

A Community-Based Educational Intervention to Improve Colorectal Cancer Screening

Suspended

Conditions: Colorectal Carcinoma

First Posted Date: 2020-05-18

Last Posted Date: 2025-01-03

Lead Sponsor: Thomas Jefferson University

Target Recruit Count: 90

Registration Number: NCT04392050

Locations: 🇺🇸
Thomas Jefferson University, Philadelphia, Pennsylvania, United States

Convalescent Plasma for the Treatment of COVID-19

Phase 2

Completed

Conditions: COVID-19

Interventions: Drug: Convalescent Plasma

First Posted Date: 2020-05-15

Last Posted Date: 2021-06-04

Lead Sponsor: Thomas Jefferson University

Target Recruit Count: 52

Registration Number: NCT04389710

Locations: 🇺🇸
Thomas Jefferson University Hospital, Philadelphia, Pennsylvania, United States

Nutritional Ketosis in Heart Failure

Phase 1

Conditions: Chronic Heart Failure

Interventions: Drug: beta hydroxybutyrate (BHB) ester
Drug: Placebo

First Posted Date: 2020-05-01

Last Posted Date: 2020-05-01

Lead Sponsor: Thomas Jefferson University

Target Recruit Count: 16

Registration Number: NCT04370600

Pharmacologic Ascorbic Acid as an Activator of Lymphocyte Signaling for COVID-19 Treatment

Phase 2

Conditions: COVID-19

Interventions: Drug: Ascorbic Acid

First Posted Date: 2020-04-27

Last Posted Date: 2020-05-05

Lead Sponsor: Thomas Jefferson University

Target Recruit Count: 66

Registration Number: NCT04363216

COVID-19 Plasma Collection

Not Applicable

Completed

Conditions: COVID-19

Interventions: Other: Plasma Donation

First Posted Date: 2020-04-14

Last Posted Date: 2021-05-10

Lead Sponsor: Thomas Jefferson University

Target Recruit Count: 206

Registration Number: NCT04344015

Locations: 🇺🇸
Thomas Jefferson University Hospital, Philadelphia, Pennsylvania, United States

Whipple Protein Study

Not Applicable

Completed

Conditions: Malnutrition
Pancreatic Cancer

Interventions: Dietary Supplement: Ensure Max Protein

First Posted Date: 2020-03-13

Last Posted Date: 2025-05-07

Lead Sponsor: Thomas Jefferson University

Target Recruit Count: 22

Registration Number: NCT04306874

Locations: 🇺🇸
Thomas Jefferson University, Philadelphia, Pennsylvania, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy